Clinical trials: Old Age; Atrophy
Sarcopenia
Amino Acid Bioavailability in Healthy Elderly After Intake of an Oral Nutritional Supplement
In this study healthy older adults are requested to consume 4 different high-protein nutritional supplements. Each subject will visit the site 4 times and at every visit they will consume 1 of the 4 products after which a series…
- Trial name
- ArenA (NCT02013466)
- Testing
- Bolus ONS A, Bolus ONS B, Bolus ONS C
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Sarcopenia
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
- Trial name
- NCT02468674
- Testing
- bimagrumab
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Sarcopenia in Elderly
A Study of PLH-2301 in Subjects With Sarcopenia
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.
- Trial name
- PLH-2301_P2 (NCT07390552)
- Testing
- PLH-2301
- Where
- 5 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Pluto Inc.
Sarcopenia in Elderly, Malnourished
The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population
Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia
- Conditions
- Sarcopenia in Elderly, Malnourished, Protein Supplementation, Muscle Mass
- Trial name
- NCT07322653
- Testing
- MediDrink Platinum+, MediDrink Platinum+ and PeptiStrong
- Where
- 2 sites in Hungary
- Volunteers
- 75 people
- Sponsor
- Nuritas Ltd
Sarcopenia
Dose Range Finding Study of Bimagrumab in Sarcopenia
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia.
- Trial name
- NCT02333331
- Testing
- bimagrumab
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Muscle Loss
Evaluate the Effect of Dietary Supplement on Muscle Mass and Physical Performance for Over 50 Years Old People
To assess the ability and safety profile of dietary supplement to augment lean body mass, muscle strength, and physical performance among people aged 50 years and older
- Trial name
- NCT04229407
- Testing
- Dietary supplement, vitamin B
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Orient Europharma Co., Ltd.
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
- Trial name
- NCT02152761
- Testing
- bimagrumab
- Where
- 53 sites in United States, Argentina and 17 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Frailty, Muscle Loss
A Randomized-Control Study of Gym Tonic's Community Based Strength Training Intervention.
Launched in April 2015 , Gym Tonic is the first of its kind cross-border exercise-as-medicine partnership between research institutions, business enterprises and service providers from Singapore and Finland.
- Conditions
- Frailty, Muscle Loss, Sarcopenia
- Trial name
- NCT04661618
- Testing
- Gym Tonic programme and Gym equipment
- Where
- Singapore
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- PulseSync Pte Ltd
Malnutrition, Sarcopenia
Health and Nutrition Status of Chinese Elderly
This study is aiming to understand the prevalence and risk factors related to malnutrition and sarcopenia in Chinese elderly.
- Trial name
- NCT02089906
- Where
- 3 sites in China
- Volunteers
- 2,834 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Sarcopenia in Elderly, Sarcopenia
A Study of AMC6156 in People With Sarcopenia
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and…
- Trial name
- NCT07072195
- Testing
- AMC6156 0.1mg, AMC6156 0.3mg, AMC6156 1.0mg
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Animuscure Inc.
Sarcopenia, Gait Disorders in Old Age
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-INT (NCT03452488)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium
- Volunteers
- 233 people
- Sponsor
- Biophytis
Atrophy, Muscular
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days
The primary objective is to determine the pharmacokinetics, safety and tolerability of SRT2104 in healthy elderly subjects following single and 28 days dosing. The secondary objectives of the study are: 1.
- Trial name
- NCT00964340
- Testing
- SRT2104
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sarcopenia
Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly
The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial…
- Trial name
- NCT03368872
- Testing
- Astaxanthin formulation, Exercise training
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Astavita, Inc.
Myotonic Dystrophy
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1).
- Trial name
- BrAAVe (NCT06844214)
- Testing
- SAR446268
- Where
- 10 sites in United States, Argentina and 4 more
- Volunteers
- 32 people
- Sponsor
- Sanofi
Duchenne Muscular Dystrophy
Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy
This is a Phase 2, multiple-dose, open-label study evaluating the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ataluren in participants aged ≥2 to <5 years old with Duchenne muscular dystrophy (DMD) caused by a…
- Trial name
- NCT02819557
- Testing
- Ataluren
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- PTC Therapeutics
Sarcopenia
Study of Efficacy and Safety of AVTR101 in Sarcopenic Elderly
The goal of this clinical trial is to primarily evaluate the efficacy of AVTR101 to placebo on physical performance in sarcopenia patients.
- Trial name
- NCT06788236
- Testing
- AVTR101
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Aventi Biotechnology Inc.
Sarcopenia in Elderly, Frailty
Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness.
- Conditions
- Sarcopenia in Elderly, Frailty, Frailty/Sarcopenia, Frailty in Older Adults
- Trial name
- NCT06942182
- Testing
- Isomyosamine 250mg
- Volunteers
- 60 people
- Sponsor
- TNF Pharmaceuticals, Inc.
Aging, Sarcopenia
Effect of Immunocal® With Exercise Versus Casein With Exercise on Aging Processes in Elderly Persons
Aging is typically associated with a decrease in skeletal muscle mass and muscle function, which contributes decisively to disability in old age and to the loss of quality of life.Resistance exercise can increase muscle strength…
- Trial name
- NCT00935610
- Testing
- Immunocal, Casein
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Immunotec Inc.
Osteoarthritis, Sarcopenia
The Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly People
The goal of this clinical trial is to learn whether Amway Nutrilite All-plant protein booster prototype product (test product) will improve sarcopenia (SA) and osteoarthritis (OA) in middle-aged and elderly people.
- Trial name
- NCT06499012
- Testing
- All-plant Protein Booster Product Group
- Where
- China
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Amway (China) R&D Center
Sarcopenia, Gait Disorders in Old Age
An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over
The SARA-OBS is a single arm phase 2 clinical trial, with no investigational product and no therapeutic intervention that will be conducted in three European countries, (Belgium, France and Italy), and in the US.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-OBS (NCT03021798)
- Testing
- No Drug and no aspecific intervention
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 218 people
- Sponsor
- Biophytis